Malignus eml őtumor? Gyulladásos emlőelváltozás? Ritka benignus kórkép?
CONCLUSION: Rosai-Dorfman disease confined to the breast is extremely rare, that clinically may mimic breast cancer.PMID:37747834 | DOI:10.1556/1046.2023.30003 (Source: Magyar Sebeszet)
Source: Magyar Sebeszet - September 25, 2023 Category: Surgery Authors: Edina Zita Kiss Ákos Botos Zolt án Szöllősi Erika T óth Source Type: research

Malignus eml őtumor? Gyulladásos emlőelváltozás? Ritka benignus kórkép?
CONCLUSION: Rosai-Dorfman disease confined to the breast is extremely rare, that clinically may mimic breast cancer.PMID:37747834 | DOI:10.1556/1046.2023.30003 (Source: Magyar Sebeszet)
Source: Magyar Sebeszet - September 25, 2023 Category: Surgery Authors: Edina Zita Kiss Ákos Botos Zolt án Szöllősi Erika T óth Source Type: research

Malignus eml őtumor? Gyulladásos emlőelváltozás? Ritka benignus kórkép?
CONCLUSION: Rosai-Dorfman disease confined to the breast is extremely rare, that clinically may mimic breast cancer.PMID:37747834 | DOI:10.1556/1046.2023.30003 (Source: Magyar Sebeszet)
Source: Magyar Sebeszet - September 25, 2023 Category: Surgery Authors: Edina Zita Kiss Ákos Botos Zolt án Szöllősi Erika T óth Source Type: research

Malignus eml őtumor? Gyulladásos emlőelváltozás? Ritka benignus kórkép?
CONCLUSION: Rosai-Dorfman disease confined to the breast is extremely rare, that clinically may mimic breast cancer.PMID:37747834 | DOI:10.1556/1046.2023.30003 (Source: Magyar Sebeszet)
Source: Magyar Sebeszet - September 25, 2023 Category: Surgery Authors: Edina Zita Kiss Ákos Botos Zolt án Szöllősi Erika T óth Source Type: research

Early chemotherapeutic intervention to avoid thyroidectomy in pediatric Langerhans cell histiocytosis with thyroid involvement accompanying tracheal stenosis: a report of two cases
In this report, we describe the cases of two children who presented with tracheal stenosis caused by thyroid LCH, both of which were successfully treated by early induction of chemotherapy, and one of which was also treated for a shorter duration. Mutation analysis detected in-frame deletions of BRAF exon 12 in both cases. These cases suggest that timely diagnosis and administration of chemotherapy may alleviate severe airway obstruction and reduce the need for thyroidectomy in pediatric patients with thyroid LCH.PMID:37740816 | DOI:10.1007/s12185-023-03662-3 (Source: International Journal of Hematology)
Source: International Journal of Hematology - September 23, 2023 Category: Hematology Authors: Shuhei Aoyama Kohei Fukuoka Hirohito Kubota Kotaro Narita Ko Kudo Yuichi Mitani Koichi Oshima Makiko Mori Yuki Arakawa Kayoko Ichimura Kiminori Terui Yutaka Tanami Hiroshi Kawashima Atsuko Nakazawa Takehiro Niitsu Yoshiyuki Takahashi Katsuyoshi Koh Source Type: research

Early chemotherapeutic intervention to avoid thyroidectomy in pediatric Langerhans cell histiocytosis with thyroid involvement accompanying tracheal stenosis: a report of two cases
In this report, we describe the cases of two children who presented with tracheal stenosis caused by thyroid LCH, both of which were successfully treated by early induction of chemotherapy, and one of which was also treated for a shorter duration. Mutation analysis detected in-frame deletions of BRAF exon 12 in both cases. These cases suggest that timely diagnosis and administration of chemotherapy may alleviate severe airway obstruction and reduce the need for thyroidectomy in pediatric patients with thyroid LCH.PMID:37740816 | DOI:10.1007/s12185-023-03662-3 (Source: International Journal of Hematology)
Source: International Journal of Hematology - September 23, 2023 Category: Hematology Authors: Shuhei Aoyama Kohei Fukuoka Hirohito Kubota Kotaro Narita Ko Kudo Yuichi Mitani Koichi Oshima Makiko Mori Yuki Arakawa Kayoko Ichimura Kiminori Terui Yutaka Tanami Hiroshi Kawashima Atsuko Nakazawa Takehiro Niitsu Yoshiyuki Takahashi Katsuyoshi Koh Source Type: research

Impact of BRAFV600E mutation on aggressiveness and outcomes in adult clonal histiocytosis
Histiocytoses encompass a wide spectrum of diseases, all characterized by tissue infiltration by CD68+ histiocytes. Most adult histiocytoses are considered clonal diseases because they highlight recurrent somatic mutations in the MAP-kinase pathway gene, primarily BRAF. The presence of BRAF mutation is associated with widespread disease in children with Langerhans cell histiocytosis (LCH) or cardiovascular/neurological involvement in Erdheim–Chester disease (ECD). Nevertheless, few data are available on adult clonal histiocytosis. This is why we have conducted a retrospective study of all patients with clonal histiocytos...
Source: Frontiers in Immunology - September 22, 2023 Category: Allergy & Immunology Source Type: research

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283295. Online ahead of print.ABSTRACTStandard treatment for Langerhans Cell Histiocytosis (LCH) is chemotherapy, with high failure rates. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEKinhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and no data exist on their use as first-line therapy. We treated thirty-four patients (26 LCH, 2 Juvenile Xanthogranuloma, 2 Rosai-Dorfman Disease, 4 presumed single site-CNS histiocytosis) with either dab...
Source: Haematologica - September 21, 2023 Category: Hematology Authors: Eily Cournoyer Justin Ferrell Susan Sharp Anish Ray Michael Jordan Christopher Dandoy Michael Grimley Somak Roy Robert Lorsbach Arnold C Merrow Adam Nelson Allison Bartlett Jennifer Picarsic Ashish Kumar Source Type: research

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283295. Online ahead of print.ABSTRACTStandard treatment for Langerhans Cell Histiocytosis (LCH) is chemotherapy, with high failure rates. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEKinhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and no data exist on their use as first-line therapy. We treated thirty-four patients (26 LCH, 2 Juvenile Xanthogranuloma, 2 Rosai-Dorfman Disease, 4 presumed single site-CNS histiocytosis) with either dab...
Source: Haematologica - September 21, 2023 Category: Hematology Authors: Eily Cournoyer Justin Ferrell Susan Sharp Anish Ray Michael Jordan Christopher Dandoy Michael Grimley Somak Roy Robert Lorsbach Arnold C Merrow Adam Nelson Allison Bartlett Jennifer Picarsic Ashish Kumar Source Type: research

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283295. Online ahead of print.ABSTRACTStandard treatment for Langerhans Cell Histiocytosis (LCH) is chemotherapy, with high failure rates. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEKinhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and no data exist on their use as first-line therapy. We treated thirty-four patients (26 LCH, 2 Juvenile Xanthogranuloma, 2 Rosai-Dorfman Disease, 4 presumed single site-CNS histiocytosis) with either dab...
Source: Haematologica - September 21, 2023 Category: Hematology Authors: Eily Cournoyer Justin Ferrell Susan Sharp Anish Ray Michael Jordan Christopher Dandoy Michael Grimley Somak Roy Robert Lorsbach Arnold C Merrow Adam Nelson Allison Bartlett Jennifer Picarsic Ashish Kumar Source Type: research

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283295. Online ahead of print.ABSTRACTStandard treatment for Langerhans Cell Histiocytosis (LCH) is chemotherapy, with high failure rates. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEKinhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and no data exist on their use as first-line therapy. We treated thirty-four patients (26 LCH, 2 Juvenile Xanthogranuloma, 2 Rosai-Dorfman Disease, 4 presumed single site-CNS histiocytosis) with either dab...
Source: Haematologica - September 21, 2023 Category: Hematology Authors: Eily Cournoyer Justin Ferrell Susan Sharp Anish Ray Michael Jordan Christopher Dandoy Michael Grimley Somak Roy Robert Lorsbach Arnold C Merrow Adam Nelson Allison Bartlett Jennifer Picarsic Ashish Kumar Source Type: research

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283295. Online ahead of print.ABSTRACTStandard treatment for Langerhans Cell Histiocytosis (LCH) is chemotherapy, with high failure rates. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEKinhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and no data exist on their use as first-line therapy. We treated thirty-four patients (26 LCH, 2 Juvenile Xanthogranuloma, 2 Rosai-Dorfman Disease, 4 presumed single site-CNS histiocytosis) with either dab...
Source: Haematologica - September 21, 2023 Category: Hematology Authors: Eily Cournoyer Justin Ferrell Susan Sharp Anish Ray Michael Jordan Christopher Dandoy Michael Grimley Somak Roy Robert Lorsbach Arnold C Merrow Adam Nelson Allison Bartlett Jennifer Picarsic Ashish Kumar Source Type: research

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283295. Online ahead of print.ABSTRACTStandard treatment for Langerhans Cell Histiocytosis (LCH) is chemotherapy, with high failure rates. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEKinhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and no data exist on their use as first-line therapy. We treated thirty-four patients (26 LCH, 2 Juvenile Xanthogranuloma, 2 Rosai-Dorfman Disease, 4 presumed single site-CNS histiocytosis) with either dab...
Source: Haematologica - September 21, 2023 Category: Hematology Authors: Eily Cournoyer Justin Ferrell Susan Sharp Anish Ray Michael Jordan Christopher Dandoy Michael Grimley Somak Roy Robert Lorsbach Arnold C Merrow Adam Nelson Allison Bartlett Jennifer Picarsic Ashish Kumar Source Type: research

Lytic Mastoid Lesion in a Patient with Otalgia
In this report, we present a patient with otalgia and an isolated lytic mastoid lesion. (Source: Head and Neck Pathology)
Source: Head and Neck Pathology - September 21, 2023 Category: Pathology Source Type: research

Targeted therapy and immunotherapy for orbital and periorbital tumors: a major review
This article will focus on recent updates in the application of available targeted and immunotherapy for managing orbital and periorbital tumors and tumor-like conditions, which include cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, cutaneous melanoma, Merkel cell carcinoma, sebaceous gland carcinoma, solitary fibrous tumor, dermatofibrosarcoma protuberans, orbital meningioma, neurofibromatosis, Langerhans cell histiocytosis, ocular adnexal lymphoma, orbital lymphatic malformation, and adenoid cystic carcinoma.PMID:37728602 | DOI:10.1080/01676830.2023.2256848 (Source: Orbit)
Source: Orbit - September 20, 2023 Category: Opthalmology Authors: Emmanuel Lee Boniao Richard C Allen Gangadhara Sundar Source Type: research